Dr. Carla Martins is a Group Leader at the MRC Cancer Unit in Cambridge, UK where she leads the “Modelling tumour development and therapy” research program. Her lab focuses on the identification and targeting of the mechanisms responsible for lung tumour progression. The research of Dr. Martins’ team is focused on lung tumours with Kras mutations, a frequent genetic mutation that so far remains untargetable. Her group recently showed that mutant Kras lung tumours are genetically and metabolically heterogeneous and that this heterogeneity can affect prognosis and response to therapy. In particular, they showed that advanced tumours exhibit a unique metabolic signature which can potentially be targeted therapeutically.